Close but no cigar for Crestor in head-to-head Lipitor study
This article was originally published in Scrip
AstraZeneca's hopes of shoring up its market share of its statin Crestor (rosuvastatin) against the onslaught of generic Lipitor have been dealt a blow with the top-line data from the SATURN study. Shares in the UK-based firm dropped by more than 3% in early trading in London on 2 September 2.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.